MedTrace Logo

Effect of Specific Immunotherapy to Dust Mites in Children With Asthma

NCT00496561 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2013-02-07

No results posted yet for this study

Summary

The aim of the study is to assess the effect of specific immunotherapy (SIT) to dust mites on clinical symptoms, reliever drugs usage, inhaled glucocorticosteroid usage, quality of life, lung function, chosen markers of inflammation, induction of regulatory lymphocytes, bronchial hyperreactivity with methacholine, and presence and type of allergy after two years of SIT in children with asthma.

Conditions

Interventions

BIOLOGICAL

subcutaneous immunotherapy (House Dust Mites)

subcutaneous immunotherapy (House Dust Mites)

OTHER

placebo of subcutaneous immunotherapy (House Dust Mites)

placebo of subcutaneous immunotherapy (House Dust Mites)

Sponsors & Collaborators

  • Medical University of Lodz

    lead OTHER

Principal Investigators

  • Iwona Stelmach, MD, PhD, Prof · Department of Pediatrics and Allergy, Medical University of Lodz, Poland

  • Dorota Jurałowicz, MD · Department of Pediatrics and Allergy, Medical University of Lodz, Poland

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2013-11-30
Completion
2013-12-31

Countries

  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00496561 on ClinicalTrials.gov